CREFTESA
pharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, tardive dyskinesia, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedo...
Pending · September 3, 2021 · 97010825 ·